{"id":744991,"date":"2014-05-06T05:00:00","date_gmt":"2014-05-06T05:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/"},"modified":"2023-03-22T00:04:55","modified_gmt":"2023-03-22T04:04:55","slug":"merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/","title":{"rendered":"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion"},"content":{"rendered":"<p class=\"bwalignc\">       Enters into Worldwide Collaboration with Bayer to Market and Develop        Novel Therapies for Cardiovascular Disease     <\/p>\n<p class=\"bwalignc\">       Collaboration Includes a $1 Billion Up-front Payment by Merck to Bayer     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that it has entered into a definitive agreement to sell<br \/>\n      its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2<br \/>\n      billion. Under the terms of the agreement, Bayer AG will acquire Merck\u2019s<br \/>\n      existing OTC business, including the global trademark and prescription<br \/>\n      rights for Claritin\u00ae and Afrin\u00ae.\n    <\/p>\n<p>\n      The company also announced a worldwide clinical development<br \/>\n      collaboration with Bayer to market and develop its portfolio of soluble<br \/>\n      guanylate cyclase (sGC) modulators. This includes Bayer\u2019s Adempas\u00ae<br \/>\n      (riociguat), the first member of this novel class of compounds. Adempas<br \/>\n      is approved to treat pulmonary arterial hypertension (PAH) and is the<br \/>\n      first and only drug treatment approved for patients with chronic<br \/>\n      thromboembolic pulmonary hypertension (CTEPH). Adempas is currently<br \/>\n      marketed in the United States and Europe for both PAH and CTEPH and in<br \/>\n      Japan for CTEPH. The two companies will equally share costs and profits<br \/>\n      from the collaboration and implement a joint development and<br \/>\n      commercialization strategy.\n    <\/p>\n<p>\n      \u201cThe sale of our consumer care business is part of our efforts to ensure<br \/>\n      that assets within our portfolio align with our core strategy, have<br \/>\n      industry-leading potential and generate long-term shareholder value,\u201d<br \/>\n      said Kenneth C. Frazier, chairman and chief executive officer, Merck.<br \/>\n      \u201cBy unlocking value in Merck Consumer Care, we\u2019re able to further our<br \/>\n      goal of being the premier research-intensive biopharmaceutical company<br \/>\n      through targeted investments that strengthen our product portfolio and<br \/>\n      enhance our pipeline.\u201d\n    <\/p>\n<p>\n      &#8220;Merck Consumer Care is a strong business with a portfolio of<br \/>\n      well-established product brands, such as Claritin, Afrin and<br \/>\n      Coppertone\u00ae, that are leaders in their respective categories,&#8221; said Dr.<br \/>\n      Marijn Dekkers, Bayer AG Chairman of the Board of Management. &#8220;The<br \/>\n      combination of Merck Consumer Care&#8217;s complementary portfolio of products<br \/>\n      and geographic reach with Bayer&#8217;s will create a global consumer care<br \/>\n      business better positioned to serve consumers around the world. We look<br \/>\n      forward to having the talents of the Merck team, with their track record<br \/>\n      of innovation, joining our strong Consumer Care team at Bayer<br \/>\n      HealthCare.&#8221;\n    <\/p>\n<p>\n      The collaboration also includes clinical development of vericiguat<br \/>\n      (BAY102), which is currently in Phase 2 trials for worsening heart<br \/>\n      failure, as well as opt-in rights for other early-stage sGC compounds in<br \/>\n      development at Bayer. Merck will in turn make available its early-stage<br \/>\n      sGC compounds under similar terms.\n    <\/p>\n<p>\n      In return for these broad collaboration rights, Bayer will receive a $1<br \/>\n      billion up-front payment with the potential for additional milestone<br \/>\n      payments upon the achievement of agreed-upon sales goals. For Adempas,<br \/>\n      Bayer will continue to lead commercialization in the Americas, while<br \/>\n      Merck will lead commercialization in the rest of the world (ROW). For<br \/>\n      vericiguat and other potential opt-in products, Bayer will lead in the<br \/>\n      ROW and Merck will lead in the Americas. For all products and candidates<br \/>\n      included in the agreement, both companies will share in development<br \/>\n      costs and profits on sales and will have the right to co-promote in<br \/>\n      territories where they are not the lead.\n    <\/p>\n<p>\n      Merck expects after-tax proceeds from the sale of MCC to be between $8<br \/>\n      and $9 billion. The company will use the after-tax proceeds &#8212;<br \/>\n      consistent with its capital allocation strategy &#8212; to resource those<br \/>\n      areas within its business that represent the highest potential growth<br \/>\n      opportunities, such as MK-3475, to augment the company&#8217;s pipeline with<br \/>\n      external assets that can create value and to continue to provide an<br \/>\n      industry-leading return of capital to shareholders.\n    <\/p>\n<p>\n      \u201cBoth Merck and Bayer have a rich history of developing and<br \/>\n      commercializing innovative products to meet significant unmet medical<br \/>\n      needs,\u201d said Frazier. \u201cOur collaboration with Bayer builds on our<br \/>\n      respective strengths, and we look forward to working with Bayer in the<br \/>\n      field of sGC modulators.\n    <\/p>\n<p>\n      \u201cThe value we obtained for our consumer business is a tribute to our<br \/>\n      colleagues who have built an outstanding business with a talented team<br \/>\n      and trusted, well-known product brands,\u201d said Frazier. \u201cWe know the<br \/>\n      strengths of our team will serve Bayer well.\u201d\n    <\/p>\n<p>\n      Merck expects to close the sale of MCC in second half of 2014, subject<br \/>\n      to customary closing conditions, including regulatory approvals. The<br \/>\n      company plans to update its 2014 financial guidance when the transaction<br \/>\n      closes.\n    <\/p>\n<p>\n      Morgan Stanley &amp; Co. LLC acted as financial advisor to Merck, and Fried<br \/>\n      Frank Harris Shriver &amp; Jacobson LLP and Morgan Lewis &amp; Bockius LLP acted<br \/>\n      as legal counsel in connection with the transaction. J.P. Morgan advised<br \/>\n      Merck with ongoing portfolio assessment leading up to the transaction.\n    <\/p>\n<p>\n      <b>Conference Call and Webcast<\/b>\n    <\/p>\n<p>\n      Merck will hold an Investor Briefing today at 9:00 a.m. EDT at its<br \/>\n      research facility in Boston, MA. During the event, members of Merck&#8217;s<br \/>\n      senior management will detail the company&#8217;s research strategy, showcase<br \/>\n      candidates from its research and development pipeline and provide a<br \/>\n      business update.\n    <\/p>\n<p>\n      There will be a live webcast of the event available on Merck&#8217;s website<br \/>\n      at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50858577&amp;newsitemid=20140506005862&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=02c103bfcd2f452002ef0fc1675838ad\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>.<br \/>\n      Software needed to listen to the webcast may be obtained on the<br \/>\n      corporate website and should be downloaded prior to the beginning of the<br \/>\n      webcast. Institutional investors, analysts and members of the media also<br \/>\n      can participate by dialing (706) 634-2289 or (877) 214-9289 and using ID<br \/>\n      code number 42688075.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50858577&amp;newsitemid=20140506005862&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=3f1e5d0ea4ca7a706cdae4815030f60a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.twitter.com%2FMerck&amp;esheet=50858577&amp;newsitemid=20140506005862&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=4e1ada21ce471de9dd5b739d7af1b286\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50858577&amp;newsitemid=20140506005862&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=804733c7d0ff39914f4c35aedfae0c51\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50858577&amp;newsitemid=20140506005862&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=303a11b3f4d3ab4f7775d08c98750dae\" rel=\"nofollow\">YouTube<\/a>.<br \/>\n      You can also follow our Twitter conversation at $MRK.\n    <\/p>\n<p>\n      <b>Bayer: Science For A Better Life<\/b>\n    <\/p>\n<p>\n      Bayer is a global enterprise with core competencies in the fields of<br \/>\n      health care, agriculture and high-tech polymer materials. As an<br \/>\n      innovation company, it sets trends in research-intensive areas. Bayer\u2019s<br \/>\n      products and services are designed to benefit people and improve their<br \/>\n      quality of life. At the same time, the Group aims to create value<br \/>\n      through innovation, growth and high earning power. Bayer is committed to<br \/>\n      the principles of sustainable development and to its social and ethical<br \/>\n      responsibilities as a corporate citizen. In fiscal 2013, the Group<br \/>\n      employed 113,200 people and had sales of \u20ac40.2 billion. Capital<br \/>\n      expenditures amounted to \u20ac2.2 billion, R&amp;D expenses to \u20ac3.2 billion. For<br \/>\n      more information, go to <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bayer.com&amp;esheet=50858577&amp;newsitemid=20140506005862&amp;lan=en-US&amp;anchor=www.bayer.com&amp;index=6&amp;md5=cfe73b8796b993bd2dbe8e4d9000cdc3\" rel=\"nofollow\">www.bayer.com<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50858577&amp;newsitemid=20140506005862&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=e794e922bff6f2aa3a16f6a022ffc8a1\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Steve Cragle, 908-423-3461<br \/>Pam Eisele,        267-305-3558<br \/>or<br \/>Investors:<br \/>Joe Romanelli, 908-423-5185<br \/>Carol        Ferguson, 908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease Collaboration Includes a $1 Billion Up-front Payment by Merck to Bayer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Merck\u2019s existing OTC business, including the global trademark and prescription rights for Claritin\u00ae and Afrin\u00ae. The company also announced a worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators. This includes Bayer\u2019s Adempas\u00ae (riociguat), the first member of this novel class of compounds. Adempas is approved to treat pulmonary arterial hypertension (PAH) and is the first and only drug treatment approved for patients with chronic thromboembolic<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[293,52,64,289],"class_list":["post-744991","news_item","type-news_item","status-publish","hentry","tag-consumer-care","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease Collaboration Includes a $1 Billion Up-front Payment by Merck to Bayer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Merck\u2019s existing OTC business, including the global trademark and prescription rights for Claritin\u00ae and Afrin\u00ae. The company also announced a worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators. This includes Bayer\u2019s Adempas\u00ae (riociguat), the first member of this novel class of compounds. Adempas is approved to treat pulmonary arterial hypertension (PAH) and is the first and only drug treatment approved for patients with chronic thromboembolic\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/\",\"name\":\"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2014-05-06T05:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion - Merck.com","og_description":"Enters into Worldwide Collaboration with Bayer to Market and Develop Novel Therapies for Cardiovascular Disease Collaboration Includes a $1 Billion Up-front Payment by Merck to Bayer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Merck\u2019s existing OTC business, including the global trademark and prescription rights for Claritin\u00ae and Afrin\u00ae. The company also announced a worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators. This includes Bayer\u2019s Adempas\u00ae (riociguat), the first member of this novel class of compounds. Adempas is approved to treat pulmonary arterial hypertension (PAH) and is the first and only drug treatment approved for patients with chronic thromboembolic","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:55+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/","name":"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2014-05-06T05:00:00+00:00","dateModified":"2023-03-22T04:04:55+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140506005862r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-sale-of-consumer-care-business-to-bayer-ag-for-14-2-billion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4d6cef07-41cb-4923-9144-945030c49ab7","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Sale-of-Consumer-Care-Business-to-Bayer-AG-for-142-Billion-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744991\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744991"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}